Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878254 | 0.90 | TLR4 (0.48) | TLR4TP53ALDH1A1TDP1 | |
| SCHEMBL28773950 | 0.85 | TLR4 (0.40) | TLR4P2RX7MAPTTP53ALDH1A1 | |
| SCHEMBL21218154 | 0.84 | TLR4 (0.44) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL28531536 | 0.84 | TLR4 (0.44) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19797161 | 0.83 | TLR4 (0.43) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19970477 | 0.82 | TLR4 (0.43) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19797164 | 0.81 | TLR4 (0.42) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19982560 | 0.79 | TLR4 (0.41) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19982519 | 0.79 | TLR4 (0.41) | TLR4P2RX7MAPTTP53LMNA | |
| SCHEMBL19982521 | 0.79 | TLR4 (0.41) | TLR4P2RX7MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-1209149-B9 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1209149-B1 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| EP-2018855-A1 | PHARMACEUTICAL AGENT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-7417059-B2 | Substituted aromatic-ring compounds, process for producing the same and use | TAKEDA PHARMACETICAL COMPANY LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1875926-A1 | STABLE EMULSION COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7078540-B1 | Substituted aromatic-ring compounds, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050176783-A1 | Substituted aromatic-ring compounds, process for producing the same and use | TAMURA NORIKAZU (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1348443-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1209149-A1 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176783-A1 | Substituted aromatic-ring compounds, process for producing the same and use | IL1B, IL1A, ARG1 | TLR4 129/4885P2RX7 3442/4885MAPT 3676/4885 |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | TLR4 567/4885P2RX7 1533/4885MAPT 4685/4885 |
| US-20090105314-A1 | Pharmaceutical Agent | TLR1, TLR6, TPMT | TLR4 8/4885P2RX7 779/4885MAPT 4175/4885 |
| US-20090062355-A1 | Pharmaceutical Product | ATF1, ATF4, TLR8 | TLR4 13/4885P2RX7 302/4885MAPT 2911/4885 |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885P2RX7 659/4885MAPT 4728/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885P2RX7 627/4885MAPT 4726/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TLR4 13/4885P2RX7 302/4885MAPT 2911/4885 |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | LIPA, PHOSPHO1, CEL | TLR4 3789/4885P2RX7 1610/4885MAPT 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.